MedPath

A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502)

Phase 2
Conditions
For patients with type 4 gastric cancer
Registration Number
JPRN-UMIN000000686
Lead Sponsor
OGSG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
31
Inclusion Criteria

Not provided

Exclusion Criteria

1.patients with severe diseases (non-treated ischemic cardiac disease, arrhythmia, liver cirrhosis, nterstitial pneumonia, fresh bleeding which needs transfusion, mental disorder, uncontrolled DM, intestinal obstruction, etc.) 2.febrile infection 3.allergy against polyoxyethylene-castor oil 4.under pregnancy or nursing 5.receiving steroids 6.receiving flucytosine, phenytoin or warfarin 7.doctors' decision

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
"The ratio of the patients who completed the regimen The ratio of administered dose to the planed dose."
Secondary Outcome Measures
NameTimeMethod
Response Rate Overall Survival Disease Free Survival Histological CR
© Copyright 2025. All Rights Reserved by MedPath